The Japanese Society of Hypertension (JSH) revised the Guidelines for the Management of
Hypertension 2014 (JSH 2014), and published the JSH 2019. In the development of the JSH …

The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline
for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

Background Persons with toxic gain-of-function variants in the gene encoding
apolipoprotein L1 (APOL1) are at greater risk for the development of rapidly progressive …

Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …

Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite
use of renin-angiotensin-aldosterone-system blockers and immunosuppressants, often …

Background: In EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients With Chronic
Heart Failure With Reduced Ejection Fraction), empagliflozin reduced cardiovascular death …

Background In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney
Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose …

There is currently an unmet need for effective treatment of chronic kidney disease (CKD) that
slows disease progression, prevents development of end-stage kidney disease and …

The original KDIGO Clinical Practice Guideline for the Management of Blood Pressure in
Chronic Kidney Disease in the chronic kidney disease (CKD) population not receiving …